Digest Network Come funziona
Network
/
Società
Tr
Non verificato

Travere Therapeutics, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza

52 comunicati stampa

Guarda tutti i comunicati
28/07/2026
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Salute
Scienza
Sanità
Farmaceutica
Biotecnologia
Travere Therapeutics to Report Second Quarter 2026 Financial Results
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0
10/07/2026
Mercato azionario
Finanza
Biotecnologia
Farmaceutica
Salute
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0
16/06/2026
Mercato del lavoro
Salute
HIV, AIDS e malattie autoimmuni
Sanità
Farmaceutica
Biotecnologia
Travere Therapeutics Announces Planned Retirement of Chief Research Officer in 2027
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0
11/06/2026
Mercato azionario
Finanza
Salute
Biotecnologia
Sanità
Scienza
Farmaceutica
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0
04/06/2026
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Eventi
Fiere
Industria
Travere Therapeutics Presents Long-Term Open-Label Extension Data from the Phase 3 DUPLEX Study at the 63rd European Renal Association (ERA) 2026 Congress
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0
02/06/2026
Igiene alimentare
Sanità
Comunicazione
Finanza
Farmaceutica
Associazioni/Professionisti
Attrezzature medico-sanitarie
Biotecnologia
Medicina - Varie
Scienza
Salute
Web e Social Network
Mercato del lavoro
Industria
Travere Therapeutics Enters Into Exclusive Licensing Agreement with Everest Medicines for Civorebrutinib a Potential Best-in-Class BTK Inhibitor for Rare Kidney Diseases
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0
27/05/2026
Industria
Biotecnologia
Igiene alimentare
Farmaceutica
Salute
Travere Therapeutics Receives Notice of Allowance from the U.S. Patent and Trademark Office for U.S. Patent Application Directed to Certain Methods of Using FILSPARI® (sparsentan) in IgA Nephropathy
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0
12/05/2026
Mercato azionario
Finanza
Salute
Biotecnologia
Sanità
Scienza
Farmaceutica
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Web e Social Network
Fiere
Eventi
Biotecnologia
Salute
Scienza
Farmaceutica
Travere Therapeutics to Participate at Upcoming Investor Conferences
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0
07/05/2026
Titoli e azioni
Scienza
Attrezzature medico-sanitarie
Biotecnologia
Management
Sanità
Salute
Farmaceutica
Travere Prices Upsized $475.0 Million Convertible Senior Notes Offering to Refinance 2029 Convertible Notes
Fonte
Travere Therapeutics, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0